Online inquiry

IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ852MR)

This product GTTS-WQ852MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ852MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8092MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ7703MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ12814MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ9721MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ6431MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ14570MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ1884MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ13076MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW